You are leaving our website

or Decline

Interim Results for the Six Months Ended 30 June 2015


("Alliance" or the "Group")

Alliance Pharma plc (AIM: APH), the speciality pharmaceutical company, is pleased to announce its interim results for the six months ended 30 June 2015.


  • Half year revenue of £22.8m (H1 2014: £21.4m)

    • Year on year revenue growth of 6.5%

  • Hydromol™ continues to grow well, with sales up 11% to £3.3m (H1 2014: £3.0m)

  • Acquisition of MacuShield™ in February 2015 contributing sales of £1.4m

  • Half year profit before tax £5.5m (H1 2014: £5.4m)

  • Basic earnings per share 1.65p (H1 2014: 1.68p)

  • Interim dividend up 10% to 0.366p (H1 2014: 0.333p)

  • Net bank debt £26.5m (31 December 2014: £21.1m)

    • £5.5m was drawn down in the first half to fund the MacuShield acquisition

  • Licensing agreement signed with Duchesnay Inc in January 2015 for the product Diclectin

“Alliance has made a positive start to 2015 with growth in both revenue and profits. We see good growth potential from MacuShield, Hydromol and other key products in our portfolio, and also from potential acquisitions. With some £18m of our acquisition bank facility still undrawn we have ample headroom for deals and are seeing an attractive pipeline of opportunities. Current trading is in line with management forecasts and we expect full year results to be in line with market expectations.”

Andrew Smith, Alliance Pharma's Chairman

For further information:

Alliance Pharma plc + 44 (0)1249 466966
Peter Butterfield, Chief Executive Officer
Andrew Franklin, Chief Financial Officer

Buchanan + 44 (0)20 7466 5000
Mark Court / Sophie Wills / Hannah Ratcliff

Numis Securities Limited + 44 (0)20 7260 1000
Nominated Adviser: Michael Meade / Freddie Barnfield
Corporate Broking: James Black

Investec Bank plc + 44 (0)20 7597 5970
Corporate Finance: Daniel Adams / Ed Thomas
Corporate Broking: Patrick Robb / Tejas Padalkar